|
gptkbp:instanceOf
|
gptkb:drug
ACE inhibitor
|
|
gptkbp:approvalYear
|
1991
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
C09AA05
|
|
gptkbp:availableOn
|
gptkb:tablet
capsule
|
|
gptkbp:bioavailability
|
28%
|
|
gptkbp:brand
|
gptkb:Altace
gptkb:Tritace
Ramace
|
|
gptkbp:CASNumber
|
87333-19-5
|
|
gptkbp:category
|
prodrug
antihypertensive agent
World Health Organization essential medicine
|
|
gptkbp:chemicalFormula
|
C23H32N2O5
|
|
gptkbp:contraindication
|
pregnancy
bilateral renal artery stenosis
history of angioedema
|
|
gptkbp:discoveredBy
|
gptkb:Hoechst_AG
|
|
gptkbp:discoveredIn
|
1981
|
|
gptkbp:eliminationHalfLife
|
13-17 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstPassMetabolism
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ramipril
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
gptkb:aliskiren
lithium
potassium-sparing diuretics
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits angiotensin-converting enzyme
|
|
gptkbp:metabolism
|
gptkb:ramiprilat
|
|
gptkbp:patent
|
1981
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
73%
|
|
gptkbp:riskFactor
|
renal impairment
teratogenicity
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
cough
hypotension
hyperkalemia
angioedema
|
|
gptkbp:usedFor
|
heart failure
hypertension
prevention of cardiovascular events
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:C09AA07
gptkb:Altace
|
|
gptkbp:bfsLayer
|
6
|